Anand A Dalal
Overview
Explore the profile of Anand A Dalal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
78
Citations
1352
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Ayyagari R, Tang D, Patterson-Lomba O, Zhou Z, Xie J, Chandiwana D, et al.
Curr Med Res Opin
. 2018 May;
34(9):1645-1652.
PMID: 29781326
Objective: To quantify the comparative efficacy of currently available endocrine-based therapies (ETs) for postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) metastatic breast cancer (mBC)...
12.
Dalal A, Guerin A, Mutebi A, Culver K
J Drug Assess
. 2018 May;
7(1):21-27.
PMID: 29707414
To describe patient characteristics, treatment patterns, healthcare resource utilization (HRU), and costs among patients with anaplastic lymphoma kinase ()-positive non-small cell lung cancer (NSCLC) receiving ceritinib in second or later...
13.
Verma S, OShaughnessy J, Burris H, Campone M, Alba E, Chandiwana D, et al.
Breast Cancer Res Treat
. 2018 Apr;
170(3):535-545.
PMID: 29654415
Purpose: Evaluate patient-reported outcomes (PROs) for postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer treated with first-line ribociclib plus letrozole. Methods: In...
14.
Ayyagari R, Tang D, Patterson-Lomba O, Zhou Z, Xie J, Chandiwana D, et al.
Clin Ther
. 2018 Apr;
40(4):628-639.e3.
PMID: 29609880
Purpose: The comparative efficacy of endocrine-based therapies (ETs) for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC) is not well characterized. This network meta-analysis (NMA) synthesized...
15.
Goldschmidt D, Dalal A, Romdhani H, Kelkar S, Guerin A, Gauthier G, et al.
Adv Ther
. 2018 Mar;
35(4):482-493.
PMID: 29582246
Introduction: Recent approval of novel agents has changed the treatment landscape for post menopausal women with hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer...
16.
Gauthier G, Gagnon-Sanschagrin P, Guerin A, Burne R, Small T, Niravath P, et al.
Adv Ther
. 2018 Mar;
35(4):503-514.
PMID: 29556908
Introduction: Premenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC) have complex treatment needs and may receive sequential combinations of endocrine therapy (ET) or...
17.
Dalal A, Guerin A, Mutebi A, Culver K
J Med Econ
. 2018 Mar;
21(7):649-655.
PMID: 29516752
Aims: To assess the time to BRAF testing, compare the characteristics of tested vs not-tested patients, and describe the costs for sequential vs next-generation sequencing (NGS) BRAF testing. Methods: Patients...
18.
Stephenson J, Wertz D, Gu T, Patel J, Dalal A
Int J Chron Obstruct Pulmon Dis
. 2017 Jul;
12:1947-1959.
PMID: 28740375
Purpose: The degree to which symptoms such as dyspnea affect patients with COPD is individualized. To address the gap between clinical symptom measures and self-perceived disease burden, we investigated the...
19.
Bendaly E, Dalal A, Culver K, Galebach P, Bocharova I, Foster R, et al.
Adv Ther
. 2017 Jun;
34(7):1673-1685.
PMID: 28578501
Introduction: Crizotinib is recommended as first-line therapy for ALK-positive non-small cell lung cancer (NSCLC), but within a year of treatment initiation many patients develop resistance. With the recent approval of...
20.
Bendaly E, Dalal A, Culver K, Galebach P, Bocharova I, Foster R, et al.
Adv Ther
. 2017 Apr;
34(5):1145-1156.
PMID: 28405961
Introduction: This study aimed to provide the first real-world description of the characteristics, treatments, dosing patterns, and early outcomes of patients with ALK-positive non-small cell lung cancer (NSCLC) who received...